Lipid motif of a bacterial antigen mediates immune responses via TLR2 signaling

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Lugade, Amit A ^a   Bianchi Smiraglia, Anna ^a   Pradhan, Vandana ^a,c   Elkin, Galina ^a   Murphy, Timothy F ^b   Thanavala, Yasmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c National Institute of Immunohaemotology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; OUTER MEMBRANE PROTEIN 6; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CD40 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN CLASS; LIPID; RECOMBINANT PROTEIN; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HAEMOPHILUS INFLUENZAE; IMMUNE RESPONSE; IMMUNOGENICITY; LIPID MOTIF; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN MOTIF; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; ENDOCYTOSIS; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; METABOLISM; SECRETION; TITRIMETRY;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; MUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, BACTERIAL; ANTIGENS, CD40; BONE MARROW CELLS; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; FEMALE; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN ISOTYPES; LIPIDS; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TITRIMETRY; TOLL-LIKE RECEPTOR 2; UP-REGULATION;

EID: 79956160564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019781     Document Type: Article

References (47)

1. Manicassamy S, Pulendran B, (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21: 185-193 S1044-5323(09)00048-7 [pii];doi:10.1016/j.smim.2009.05.005.
2. Pulendran B, Ahmed R, (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863 S0092-8674(06)00194-2 [pii];doi:10.1016/j.cell.2006.02.019.
3. Fransen F, Boog CJ, van Putten JP, van der Ley P, (2007) Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun 75: 5939-5946 IAI.00846-07 [pii];doi:10.1128/IAI.00846-07.
4. Nussbaum G, Ben-Adi S, Genzler T, Sela M, Rosen G, (2009) Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun 77: 3939-3947 IAI.00488-09 [pii];doi:10.1128/IAI.00488-09.
5. Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, et al. (2000) Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 19 (Suppl 1): S108-S115 S0264410X00002887 [pii].
6. Bolduc GR, Bouchet V, Jiang RZ, Geisselsoder J, Truong-Bolduc QC, et al. (2000) Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous, multifaceted approach. Infect Immun 68: 4505-4517.
7. Neary JM, Yi K, Karalus RJ, Murphy TF, (2001) Antibodies to loop 6 of the P2 porin protein of nontypeable Haemophilus influenzae are bactericidal against multiple strains. Infect Immun 69: 773-778 doi:10.1128/IAI.69.2.773-778.2001.
8. Murphy TF, (2005) Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 4: 843-853 doi:10.1586/14760584.4.6.843.
9. Badr WH, Loghmanee D, Karalus RJ, Murphy TF, Thanavala Y, (1999) Immunization of mice with P6 of nontypeable Haemophilus influenzae: kinetics of the antibody response and IgG subclasses. Vaccine 18: 29-37.
10. Green BA, Metcalf BJ, Quinn-Dey T, Kirkley DH, Quataert SA, et al. (1990) A recombinant non-fatty acylated form of the Hi-PAL (P6) protein of Haemophilus influenzae elicits biologically active antibody against both nontypeable and type b H. influenzae. Infect Immun 58: 3272-3278.
11. Abe Y, Murphy TF, Sethi S, Faden HS, Dmochowski J, et al. (2002) Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165: 967-971.
12. Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, et al. (2004) Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships. Vaccine 22: 2494-2499 doi:10.1016/j.vaccine.2003.11.074;S0264410X04002610 [pii].
13. McMahon M, Murphy TF, Kyd J, Thanavala Y, (2005) Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity. Vaccine 23: 3590-3596 S0264-410X(05)00258-6 [pii];doi:10.1016/j.vaccine.2005.01.151.
14. Adlowitz DG, Sethi S, Cullen P, Adler B, Murphy TF, (2005) Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis. Infect Immun 73: 6601-6607 73/10/6601 [pii];doi:10.1128/IAI.73.10.6601-6607.2005.
15. Iweala OI, Smith DW, Matharu KS, Sada-Ovalle I, Nguyen DD, et al. (2009) Vaccine-induced antibody isotypes are skewed by impaired CD4 T cell and invariant NKT cell effector responses in MyD88-deficient mice. J Immunol 183: 2252-2260 jimmunol.0804011 [pii];doi:10.4049/jimmunol.0804011.
16. Chandran SS, Verhoeven D, Teijaro JR, Fenton MJ, Farber DL, (2009) TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J Immunol 183: 7832-7841 jimmunol.0901683 [pii];doi:10.4049/jimmunol.0901683 [doi].
17. Mineo TW, Oliveira CJ, Gutierrez FR, Silva JS, (2010) Recognition by toll-like receptor 2 induces antigen-presenting cell activation and Th1 programming during infection by Neospora caninum. Immunol Cell Biol icb201052 [pii];doi:10.1038/icb.2010.52.
18. Jin H, Kumar L, Mathias C, Zurakowski D, Oettgen H, et al. (2009) Toll-like receptor 2 is important for the T(H)1 response to cutaneous sensitization. J Allergy Clin Immunol 123: 875-882 S0091-6749(09)00233-4 [pii];doi:10.1016/j.jaci.2009.02.007.
19. van RE, Everts B, Retra K, Phylipsen M, van Hellemond JJ, et al. (2009) Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization. BMC Immunol 10: 9 1471-2172-10-9 [pii];doi:10.1186/1471-2172-10-9.
20. Wenink MH, Santegoets KC, Broen JC, van BL, Abdollahi-Roodsaz S, et al. (2009) TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J Immunol 183: 6960-6970 jimmunol.0900713 [pii];doi:10.4049/jimmunol.0900713.
21. Dillon S, Agrawal A, Van DT, Landreth G, McCauley L, et al. (2004) A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 172: 4733-4743.
22. Lombardi V, Van OL, Horiot S, Moussu H, Chabre H, et al. (2008) Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 38: 1819-1829 CEA3056 [pii];doi:10.1111/j.1365-2222.2008.03056.x.
23. Patel M, Xu D, Kewin P, Choo-Kang B, McSharry C, et al. (2005) TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 174: 7558-7563 174/12/7558 [pii].
24. Nomura Y, Abe Y, Ishida Y, Kobayashi H, Harabuchi Y, (2008) Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein. J Clin Immunol 28: 361-369 doi:10.1007/s10875-008-9189-0.
25. Ishida Y, Abe Y, Yanai M, Kobayashi H, Harabuchi Y, (2006) Identification of human T-cell epitopes and highly immunogenic analog peptides on the non-typeable Haemophilus influenzae P6 outer membrane protein. Clin Immunol 121: 90-99 S1521-6616(06)00777-7 [pii];doi:10.1016/j.clim.2006.06.005.
26. Chiu YC, Lin CY, Chen CP, Huang KC, Tong KM, et al. (2009) Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1- dependent pathway. J Immunol 183: 2785-2792 jimmunol.0802826 [pii];doi:10.4049/jimmunol.0802826.
27. Pejoski D, Zeng W, Rockman S, Brown LE, Jackson DC, (2010) A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol icb201015 [pii];doi:10.1038/icb.2010.15.
28. Chua BY, Zeng W, Jackson DC, (2008) Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol Biol 494: 247-261 doi:10.1007/978-1-59745-419-3_14.
29. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101: 15440-15445 0406740101 [pii];doi:10.1073/pnas.0406740101.
30. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L, (2004) Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 34: 3102-3114 doi:10.1002/eji.200425166.
31. Bettahi I, Zhang X, Afifi RE, BenMohamed L, (2006) Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol 19: 220-236 doi:10.1089/vim.2006.19.220.
32. Kiura K, Kataoka H, Yasuda M, Inoue N, Shibata K, (2006) The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses. FEMS Immunol Med Microbiol 48: 44-55 FIM119 [pii];doi:10.1111/j.1574-695X.2006.00119.x.
33. Chen R, Lim JH, Jono H, Gu XX, Kim YS, et al. (2004) Nontypeable Haemophilus influenzae lipoprotein P6 induces MUC5AC mucin transcription via TLR2-TAK1-dependent p38 MAPK-AP1 and IKKbeta-IkappaBalpha-NF-kappaB signaling pathways. Biochem Biophys Res Commun 324: 1087-1094 S0006-291X(04)02215-6 [pii];doi:10.1016/j.bbrc.2004.09.157.
34. Punturieri A, Copper P, Polak T, Christensen PJ, Curtis JL, (2006) Conserved nontypeable Haemophilus influenzae-derived TLR2-binding lipopeptides synergize with IFN-beta to increase cytokine production by resident murine and human alveolar macrophages. J Immunol 177: 673-680 177/1/673 [pii].
35. Pasare C, Medzhitov R, (2005) Control of B-cell responses by Toll-like receptors. Nature 438: 364-368 nature04267 [pii];doi:10.1038/nature04267.
36. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, et al. (2006) Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314: 1936-1938 314/5807/1936 [pii];doi:10.1126/science.1135299.
37. Meyer-Bahlburg A, Khim S, Rawlings DJ, (2007) B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med 204: 3095-3101 jem.20071250 [pii];doi:10.1084/jem.20071250.
38. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H, (2005) Expression of toll-like receptors on B lymphocytes. Cell Immunol 236: 140-145 S0008-8749(05)00166-8 [pii];doi:10.1016/j.cellimm.2005.08.020.
39. Gururajan M, Jacob J, Pulendran B, (2007) Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2 doi:10.1371/journal.pone.0000863.
40. Barr TA, Brown S, Ryan G, Zhao J, Gray D, (2007) TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol 37: 3040-3053 doi:10.1002/eji.200636483.
41. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF, (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182: 7459-7472 182/12/7459 [pii];doi:10.4049/jimmunol.0900270 [doi].
42. Johnson TR, Rao S, Seder RA, Chen M, Graham BS, (2009) TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27: 3045-3052 S0264-410X(09)00432-0 [pii];doi:10.1016/j.vaccine.2009.03.026.
43. Borsutzky S, Kretschmer K, Becker PD, Muhlradt PF, Kirschning CJ, et al. (2005) The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174: 6308-6313 174/10/6308 [pii].
44. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, et al. (2007) Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25: 763-775 S0264-410X(06)00956-X [pii];doi:10.1016/j.vaccine.2006.08.013.
45. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214 S0264-410X(07)01256-X [pii]; doi:10.1016/j.vaccine.2007.10.062.
46. Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3 doi:10.1371/journal.pone.0002257.
47. Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, et al. (2008) New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26: 6132-6142 S0264-410X(08)01198-5 [pii];doi:10.1016/j.vaccine.2008.08.070.